home / stock / ntra / ntra news


NTRA News and Press, Natera Inc. From 08/01/22

Stock Information

Company Name: Natera Inc.
Stock Symbol: NTRA
Market: NASDAQ
Website: natera.com

Menu

NTRA NTRA Quote NTRA Short NTRA News NTRA Articles NTRA Message Board
Get NTRA Alerts

News, Short Squeeze, Breakout and More Instantly...

NTRA - Natera Announces Second Quarter 2022 Earnings Conference Call

Natera Announces Second Quarter 2022 Earnings Conference Call PR Newswire AUSTIN, Texas , Aug. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its seco...

NTRA - Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents

Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents PR Newswire AUSTIN, Texas , July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced th...

NTRA - Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer

Natera ( NASDAQ: NTRA ) on Monday said Medicare coverage for its Signatera diagnostic test had been extended to patients with muscle invasive bladder cancer, effective April 19. The company said it had received written confirmation on the extension of coverage from the...

NTRA - Medicare Extends Coverage of Natera's Signatera(TM) MRD Test to Muscle Invasive Bladder Cancer

Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer PR Newswire AUSTIN, Texas , July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it...

NTRA - Natera Selected for UnitedHealthcare's Preferred Laboratory Network

Natera Selected for UnitedHealthcare's Preferred Laboratory Network PR Newswire AUSTIN, Texas , July 14, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced it has been selected to partic...

NTRA - Lantheus Holdings Rules The Medical Diagnostics Business World

Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio’s near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad...

NTRA - Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study

Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study PR Newswire Statistically significant performance improvement from using both dd-cfDNA fraction and dd-cfDNA q...

NTRA - Nothing Compelling About Natera

Shares of diagnostic testing concern Natera are down 70% from their all-time high set in September 2021, as the biotech sector and high-growth no-profit names get pummeled. Additionally, the company is dogged by allegations of fraudulent and unethical marketing practices, included in ...

NTRA - Tackling Recurring Health Conditions Offers Hope to Patients

Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly in the case of cancer or heart conditions. This reality is enc...

NTRA - Kessler Topaz, Meltzer & Check, LLP Encourages Natera, Inc. Investors with Substantial Losses to Contact the Firm

Radnor, Pennsylvania--(Newsfile Corp. - June 11, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities ...

Previous 10 Next 10